Finzati - Logo
EMBC logo

Embecta Corp.

EMBC • Drug Manufacturers - Specialty & Generic
$0.00
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Solid company profile with reasonable valuation support. The data suggests a balanced quality/value setup.
Market Cap
$262.23M
Growth
-0.8%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 8.8%Positive free cash flow · 3.13Consistent free cash flow · 5/5Reasonable earnings multiple · 8.62Healthy liquidity · 2.41
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 9, 2026, 12:13 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$262.23M
52W Range2.77 - 15.55
Beta0.81
Gross Margin62.89%
Oper. Margin30.48%
Profit Margin8.83%
Debt/Eq-2.20
Current Ratio2.41
Quick Ratio1.73
Revenue 5Y-0.81%

Investment DNA

How strong this company looks for long-term investors

70
out of 100
Business Quality
Margins, moat, returns
66/100
Financial Strength
Debt, cash, stability
74/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
94/100
Why this score▼
Stable or improving margins · 8.8%Positive free cash flow · 3.13Consistent free cash flow · 5/5Reasonable earnings multiple · 8.62Healthy liquidity · 2.41Negative growth trend

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-08-09
Low
$5.00
Mean
$5.00
Median
$5.00
High
$5.00

Company Overview

IPO: 3/22/2022
Industry: Drug Manufacturers - Specialty & Generic
P/B i: -1.26
Debt / Equity i: -2.20
Operating Margin: 30.48%
Net Margin: 8.83%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: -2.20
Current Ratio: 2.41
Quick Ratio: 1.73
Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected
Roth Anthony M.
Transaction: 06/01/2026
BUY
Change
+30,000
Price
Not reported
Filing
06/02/2026
Type
BUY
Reidy Christopher R
Transaction: 02/11/2026
BUY
Change
+22,841
Price
Not reported
Filing
02/13/2026
Type
BUY
Pomeroy Claire
Transaction: 02/11/2026
BUY
Change
+22,841
Price
Not reported
Filing
02/13/2026
Type
BUY